Previous research on patients with inflammatory bowel disease (IBD) has identified several genes (IL13RA2, TNFRSF11B, STC1, IL-6, and IL-11) that constitute potential biomarkers that can identify patients with limited response to IFX, which is consistent with our study (12, 23). This evidence concerns the gene IL11 and inflammatory bowel disease.